Case Summary (G.R. No. 121267)
Key Dates
Patent issued: November 29, 1978.
Compulsory license petition filed with BPTTT by Danlex: August 21, 1989.
Court of Appeals decision affirming BPTTT: January 27, 1995.
Supreme Court decision (G.R. No. 121267): October 23, 2001.
Applicable Law and Legal Framework
Primary statutory framework applied: Republic Act No. 165 (the Patent Law, 1947, as amended), particularly Section 34 (grounds for compulsory licensing), Section 35 (grant of license), and Section 35-B (terms and conditions of compulsory license, including royalty ceilings).
International treaty cited: Paris Convention for the Protection of Industrial Property, Article 5 provisions invoked by petitioner.
Constitutional context: Because the Supreme Court decision date is after 1990, the analysis is situated within the framework of the 1987 Philippine Constitution (the prompt does not attribute specific constitutional provisions to the Court’s reasoning).
Procedural History
Danlex filed a compulsory license petition before the BPTTT in 1989 under Section 34(1)(e) of RA 165, asserting that cimetidine is a medicinal product and that Danlex was capable of using the patented product in manufacture. The BPTTT granted a compulsory license allowing Danlex to use, manufacture and sell its own brand of cimetidine-containing pharmaceuticals and fixed royalties at 2.5% of net sales in Philippine currency. Smith Kline & French appealed to the Court of Appeals, which affirmed the BPTTT decision on January 27, 1995. Petitioner’s motions for reconsideration and for injunctive relief were denied by the Court of Appeals. Petitioner then filed a petition for review on certiorari with the Supreme Court.
Facts Found by the BPTTT and Accepted on Review
- The patented product is medicinal in nature (cimetidine, useful as an antihistamine and in the treatment of ulcers).
- More than ten years had elapsed since issuance of the patent, and the petition for a compulsory license sought to allow manufacture and sale of a medicinal product.
- Danlex demonstrated capability to work the patented product or to employ it in manufacturing a useful product.
- Publication requirements under the Patent Law were found by the BPTTT and the Court of Appeals to have been satisfied (petitioner later contested the adequacy of proof of publication).
Issues Presented to the Supreme Court
- Whether the grant of the compulsory license by the BPTTT under Section 34 constituted a valid exercise of police power and was supported by law and fact.
- Whether Section 34 (and the BPTTT’s exercise under it) violated the Paris Convention by providing grounds for compulsory licensing beyond those enumerated in the Convention.
- Whether the royalty fixed by the BPTTT at 2.5% of net sales amounted to an uncompensated taking or otherwise was unreasonable.
- Whether the BPTTT acquired jurisdiction over Danlex’s petition given alleged noncompliance with publication requirements under the Patent Law.
Supreme Court’s Analysis — Validity of Compulsory License
The Court affirmed the BPTTT and Court of Appeals holdings that the grant complied with Section 34 of RA 165. Section 34 permits applications for compulsory licenses after two years from the grant of a patent where the patented invention relates to food or medicine or is necessary for public health or safety (Section 34(1)(e)). The Court emphasized that the statutory prerequisites were met: the patent had been issued over ten years previously and the application concerned a medicinal article; Danlex had shown capability to work the invention or to use it in manufacture, satisfying Section 34(2). The Court recognized that compulsory licensing under the statute is intended both to ensure public supply and to prevent the building up of patent monopolies.
Supreme Court’s Analysis — Paris Convention Issue
The Court rejected petitioner’s contention that Section 34 of RA 165 contravenes the Paris Convention. It relied on Article 5, Section A(2) of the Paris Convention, which permits member countries to adopt measures providing for compulsory licenses to prevent abuses that might result from the exercise of patent rights (failure to work being an illustrative example). The Court held that the Convention allows national legislative measures addressing abuses beyond the specific example of failure to work; therefore Section 34’s enumerated grounds, including public health grounds, are consistent with the Convention. The Court referenced prior case law reaching the same conclusion.
Supreme Court’s Analysis — Potential Confusion Over Source of Invention
Petitioner argued that a compulsory license would confuse the public into believing Danlex was the originator of cimetidine. The Court found this concern unfounded, noting that the licensee expressly acknowledges the patentee as the source of the patented product. Even if some confusion were possible, the Court concluded the public benefit (increased supply and lower prices) outweighed such disadvantages.
Supreme Court’s Analysis — Royalties and Expropriation Argument
Petitioner asserted that the 2.5% royalty was grossly inadequate and constituted an uncompensated taking. The Court held there was no deprivation of property without just compensation because the patentee had already enjoyed exclusive rights for at least two years from the patent grant, and the statutory scheme provides for remuneration to the patentee in the form of royalties under compulsory licensing. The Court pointed to Section 35-B(3), which caps royalties at 5% of the net wholesale price (and
...continue readingCase Syllabus (G.R. No. 121267)
Case Citation and Court
- Reported as 420 Phil. 10; 99 OG No. 9, 76 (March 3, 2003).
- Decided by the Supreme Court, First Division, G.R. No. 121267, October 23, 2001.
- Decision authored by Justice Kapunan; concurrence by Davide, Jr., C.J. (Chairman), Puno, Pardo, and Ynares-Santiago, JJ.
Parties and Posture
- Petitioner: Smith Kline & French Laboratories, Ltd. (assignee of Letters Patent No. 12207 covering Cimetidine).
- Private respondent / defendant-appellant: Danlex Research Laboratories, Inc. (sought compulsory license).
- Also involved in prior stages: Bureau of Patents, Trademarks and Technology Transfer (BPTTT) as public respondent; Court of Appeals as respondent in the petition for review on certiorari.
- Procedural posture: Petition for review on certiorari filed by petitioner from Court of Appeals Decision dated January 27, 1995 affirming BPTTT grant of compulsory license; Court of Appeals Resolution of July 25, 1995 denying motion for reconsideration also assailed.
Patent and Subject Matter
- Patent involved: Letters Patent No. 12207 covering the pharmaceutical product Cimetidine.
- Patent issued to Graham John Durant, John Collin Emmett and Robin Genellin on November 29, 1978; petitioner is assignee of the patent.
- Technical scope in source: relates to derivatives of heterocyclic thio or lower alkoxy or amino lower alkyl thiourea, ureas or guanadines.
- Functional description in source: Cimetidine is useful as an antihistamine and in the treatment of ulcers; classified as a medicinal/pharmaceutical product.
Petition for Compulsory License — Filing and Grounds
- Date of filing: August 21, 1989 — private respondent Danlex filed a petition with BPTTT for a compulsory license to manufacture and produce its own brand of medicines using Cimetidine.
- Statutory provision invoked: Section 34(1)(e) of Republic Act No. 165 (the Patent Law as then governing patents).
- Substance of Section 34(1)(e) as invoked: application for compulsory license may be filed any time after lapse of two (2) years from date of grant if the patented invention or article relates to food or medicine or manufactured substances usable as food or medicine, or is necessary for public health or public safety.
- Allegations in petition: Cimetidine is medicinal and useful; private respondent capable of using the patented product in the manufacture of a useful product.
Petitioner’s Opposition to the Petition for Compulsory License
- Main contentions asserted by petitioner before BPTTT and later on appeal:
- Private respondent had no cause of action and failed to allege specifically how it intended to work the patented product.
- Petitioner’s own manufacture, use and sales satisfied Philippine market needs; no necessity for a compulsory license.
- Granting compulsory license would not promote public safety and was motivated by pecuniary gain.
- Challenge to jurisdictional requirement: claimed failure of publication required by law, contesting BPTTT’s acquisition of jurisdiction.
- On appeal and in the petition for review: asserted that BPTTT decision violated the Paris Convention; that the grant was an invalid exercise of police power; that the royalty fixed (2.5% of net sales in peso) was without factual basis and amounted to expropriation without just compensation.
Decision of the BPTTT
- BPTTT ruling: ordered issuance of a compulsory license to Danlex for use, manufacture and sale in the Philippines of its own brand of pharmaceutical products containing Cimetidine.
- Monetary condition: ordered payment by private respondent to petitioner of royalties at the rate of 2.5% of net sales in Philippine currency.
- BPTTT findings as recited: declared private respondent capable of working the patented product or making use of it in the manufacture of a useful product.
Court of Appeals Decision (January 27, 1995)
- Dispositive paragraph: Petition for review by petitioner denied; decision of BPTTT affirmed; costs against petitioner.
- Key holdings and reasoning summarized by the Court of Appeals and affirmed by the Supreme Court:
- The grant of compulsory license to Danlex was in accord with the Patent Law because Cimetidine is medicinal and thus falls within Section 34(1)(e) as necessary for public health and public safety.
- Purpose of compulsory licensing: not only to give others chance to supply public with quantity of the patented article but especially to prevent growth of patent monopolies.
- The royalty rate of 2.5% of net sales was not unreasonable given that the license was for manufacturing only, without technical assistance from petitioner, and similar rates had been prescribed in other patent cases.
- Private respondent complied with the publication requirement; proof of compliance was submitted.
- Rejected petitioner’s contention that compulsory license would cause public confusion as to origin; licensee explicitly acknowledges patentee as source.
- Rejected petitioner’s claim of expropriation without just compensation; emphasized that patentee still entitled to remuneration by way of royalties.
- Found no error in BPTTT’s exercise of discretion in fixing royalty rate under statutory framework.
Petition to the Supreme Court — Assignments of Error
- Petitioner’s specific assignments of error on appeal to the Supreme Court:
- Court erred in upholding BPTTT decision as arbitrary exercise of police power and violative of international law (Paris Convention).
- Court erred in holding that compulsory licensing will not create confusion that Cimetidine is the brainchild of Danlex and not petitioner.
- Even if compulsory license proper, Court erred in finding BPTTT’s royalty of 2.5% of net wholesale price in peso does not amount to expropriation without just compen